/ / Investor Presentation April 2021
//
Investor PresentationApril 2021
//
Forward-Looking Statements Disclosure
12 April 2021 2
This presentation will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements other than statements of historical facts contained in this presentation, including statements
regarding our future results of operations and financial position, business strategy, prospective products, availability of
funding, ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements, the scope,
progress, results and costs of developing our products or any other future products, the potential market size and size of the
potential patient populations for our products, the timing and likelihood of success of obtaining product approvals, plans and
objectives of management for future operations, the scope of protection we are able to establish and maintain for
intellectual property rights covering our products, and future results of anticipated products, are forward-looking statements.
These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different from any future results, performance or achievements
expressed or implied by the forward-looking statements. All statements made on this call that do not relate to matters of
historical fact should be considered forward-looking statements. Factors that may cause results to differ from these forward-
looking statements are discussed under the Forward-Looking Statements section in the company’s most recent 10K and
other periodic filings with the Securities and Exchange Commission (SEC).
Any forward-looking statements provided during this presentation, including projections for future performance, are based
on management’s expectations as of today. Acutus undertakes no obligation to update these statements, except as
required by applicable law.
Leading the Charge in the EP Revolution
4/12/2021 3
We are a therapy management company
developing comprehensive and innovative solutions
to treat cardiac arrythmias
Contact
Diagnostic
Solutions**
Gold Tip Ablation Therapy*
Access Guides & Sheaths
High Density Non-Contact Advanced Mapping
Ultrasound Integrated 3DNon-Contact
Mapping SystemStrategic
Partnerships
Expert Clinical
& Product
Support
* CE Mark - Not approved for use in the United States
** - Some products not manufactured by Acutus Medical
Our vision is to become the partner-of-choice for
electrophysiologists and hospitals around the world
through our portfolio of access, diagnostic,
imaging, and therapy products
We will execute our strategy and drive shareholder
value through technology and innovation leadership,
commercial execution, and operational excellence
//
Our Markets are Large, Growing, and Underpenetrated
12 April 2021 4
~$5.7 Billion*~1.1 million
ablation procedures
10-15%Annual growth rate of
ablation procedures
worldwide (2015-2019)
Progressive disease,
function of aging
Western
lifestyleIncreasing utilization of
self monitoring devices
Well established
reimbursement in
developed markets
Key drivers: Growing incidence and diagnosis of cardiac arrhythmias
Sources: Electrophysiology Mapping and Ablation Devices, Market Insights, US. Decision Resources Group M360EP0059, June 2019, American Hospital Association, Center
for Disease Control and Prevention, European Heart Rhythm Association, Internal Estimates
<5%Current global
penetration of
prevalence pool
*Estimated 2019 value of disposables segment
//
Unmet Need: Lack of Options for Complex Patient Population
12 April 2021 5
>50% of procedures for
paroxysmal (early/simple
patients); while complex patients
represent nearly ~70% of
prevalence pool
Sources: Electrophysiology Mapping and Ablation Devices, Market Insights, US. Decision Resources Group M360EP0059, June 2019, American Hospital Association, Center
for Disease Control and Prevention, European Heart Rhythm Association, Internal Estimates
Complex patient population left with few good options
Landmark studies have
shown success rates at
~50% (defined as
freedom from atrial
fibrillation at 12-months)
Procedure times can
range 2-6 hours
Few dedicated
treatment options for
complex patients
Lengthy and
complicated nature of
conventional mapping
and ablation
techniques
Relatively poor
clinical outcomes
//
Unique Electrophysiology Therapy Guidance Platform
12 April 2021 6
Workstation and Console
48 High FidelityLow Impedance Electrodes
48 UltrasoundTransducers
0.032” (0.81mm)Guidewire Compatible
Non-Contact 3D Imaging and Mapping Catheter Compatible with Conventional Mapping Catheters
➢ Whole chamber anatomy and electrical maps in under 3 minutes➢ Facilitates map, ablate, re-map
➢ Open platform➢ Workhorse system for less complex cases
// 12 April 2021 7
Impediments To
PenetrationParoxysmal AF Persistent AF
Long Standing
Persistent AFAtypical Flutter
Complex
Tachycardia
Other Atrial
Arrhythmias
Ventricular
Tachycardia
(Research) (2)
~23% ~15% ~6% ––––––––––––––– Remaining ~48% –––––––––––– ~8%
Long Procedures
Procedures of
Unpredictable Duration
Poor Outcomes at
Ablation
Extreme MD Skill
Required
General Cardiologists
Reluctant to Refer
High Benefit Significant Benefit Benefit
Atrial Fibrillation Supraventricular Tachycardias
Percentages above based on company estimates of ~1,081k WW electrophysiology procedures in 2019 including 475k atrial fibrillation procedures (of which 53% were for paroxysmal atrial
fibrillation, 33% were for persistent atrial fibrillation and 14% were for long-standing persistent atrial fibrillation), 516k SVT procedures and 90k VT procedures
(1) Based on internal Company estimates
(2) AcQMap catheter is not currently indicated for use in the ventricle
Why Is the Market Less Than 5% Penetrated?(1)
How and Where Acutus Can Add Value / Solve Problems
// 12 April 2021 8
Variable
Acutus
UNCOVER AF
12M [1]
N = 127
Biosense
PRECEPT
15M [2]
N = 381
AtriCure
CONVERGE
Endo Only
12M [3]
N = 51
AtriCure
CONVERGE
Convergent
12M [3]
N = 102
Abbott
STAR AF II
PVI
12M [4]
N = 61
Abbott
STAR AF II
PVI + CFAE
12MN = 244
Abbott
STAR AF II
PVI + Lines
12MN = 244
Patient Population Persistent AF Persistent AFPersistent & Long-Standing
Persistent AFPersistent AF
Re-ablation allowed in “blanking period” None 3 - 6 Months None None 3 Months 3 Months 3 Months
Freedom from AF > 30 s after one
procedure, with or without AAD73% NR 51% 71% 61% 54% 50%
Freedom from AF > 30 s after multiple
procedures, with or without AAD*93% NR NR NR 79% 70% 70%
Freedom from AF/AT/AFL > 30 s after
one procedure, with or without AAD69.2% 61.7% 49% 67.5% 52% 48% 44%
UNCOVER AF (AcQMap): We believe fundamentally different mapping approach & therapy strategy (non-contact
mapping & map/treat/re-map strategy) leads to improved success rates 1: Willems et al; Charge Density Mapping for Atrial Fibrillation:Circ Arrhythm Electrophysiol. 2019;12:e007233.
2: Mansour M, et. al; Persistent atrial fibrillation ablation with contact force sensing catheter: The prospective multicenter PRECEPT Trial, JACC: Clinical Electrophysiology (2020)
3: De Lurgio D et. al; Hybrid Convergent Procedure: Epicardial and Endocardial Ablation for the Treatment of Persistent Atrial Fibrillation -CONVERGE Randomized Controlled Clinical Trial Results, HRS Late-Breaking Clinical Trials (2020)
4: Verma A, et al; Approaches to Catheter Ablation for Persistent Atrial Fibrillation N Engl J Med 2015;372:1812-22. Estimated from KM curve data available in NEJM
*Outcome comparisons are difficult due to difference in the detailed effectiveness outcome definitions
NR = Not Reported
Acutus Comparative Outcomes for Persistent AF*Meaningful Clinical Improvement vs. Stagnant Standard of Care
//
Traditional Approaches and Products in Persistent AF Yield Disappointing Results
12 April 2021 9
50% 49%46%
39%
29%27%
12.5%
0%
25%
50%
75%
100%
Abbott
N = 244Atricure
N = 51
Abbott
N =244
Abbott
N = 61Atricure
N = 102Acutus
N = 127
STAR-AF 2 [4]
PVI + Lines
CONVERGE [3]
PVI – Control
Arm
STAR-AF 2
PVI + CFAE
STAR-AF 2
PVI OnlyCONVERGE
Therapy Arm
UNCOVER AF [1]
PVI + Core-To-
Boundary
Individualized Tx
INVESTIGATOR
SPONSORED [2]
PVI + Core-To-
Boundary
Individualized Tx
Freedom from AF may be maintained for a longer
duration with a Core-to-Boundary Strategy
Failure back into AF within 12 months in significant trials
(using contact mapping and traditional ablation strategies)
73%SUCCESS
87.5%SUCCESS
1: Willems et al; Charge Density Mapping for Atrial Fibrillation:Circ Arrhythm Electrophysiol. 2019;12:e007233.
2: Shi, et al. Heart Rhythm. 2021; S1547-5271(21)00136-3 DOI: https://doi.org/10.1016/j.hrthm.2021.02.014
3: De Lurgio D et. al; Hybrid Convergent Procedure: Epicardial and Endocardial Ablation for the Treatment of Persistent Atrial Fibrillation -CONVERGE Randomized Controlled Clinical Trial Results, HRS Late-Breaking Clinical Trials (2020)
4: Verma A, et al; Approaches to Catheter Ablation for Persistent Atrial Fibrillation N Engl J Med 2015;372:1812-22. Estimated from KM curve data available in NEJM
*Outcome comparisons are difficult due to difference in the detailed effectiveness outcome definitions
NR = Not Reported
Oxford & Royal
Brompton
N = 40
24
MO
NT
HS
//
Comprehensive Product Portfolio, Transformative Technology for Electrophysiologists
12 April 2021 10
Patient Electrode Kit
Large Bore Steerable Sheath
AcQGuide MAX
Dual Purpose IntroducerAcQRef
Septal CrossingAcQCross Qx
ICE Catheter*Innovative HealthReprocessed
Fixed Curve SheathAcQGuide MINI
Small Bore Steerable SheathAcQGuide FLEX
Diagnostic Mapping Catheters,
Accessories
High Density Atrial /Ventricular Mapping
AcQMap 3D Imaging and Mapping Catheter
Innovative Health Reprocessed*
Ablation CathetersAcQBlate Gold Force Sensing
and Conventional
Partnerships*Stereotaxis
Biotronik
Image Integration*Ϯ
* Partnerships
Ϯ Development, not currently marketed
//
Completing the Continuum: Access, Diagnostics, Therapy, and Monitoring
12 April 2021 11
Transseptal Access Mapping & Diagnostics Therapy Monitoring
AcQ
Cro
ss T
ran
sse
pta
l S
yste
m
AcQ
Cro
ss +
MIN
I
AcQ
Cro
ss +
FL
EX
AcQ
Cro
ss +
VZ
AcQ
Cro
ss +
SW
AcQ
Cro
ss +
AG
AcQ
Cro
ss +
SL
AcQ
Gu
ide
MA
X
AcQ
Gu
ide
VU
E
AcQ
Ma
p C
ath
ete
r
AcQ
Ma
p C
on
so
le
AcQ
Map P
atient E
lectr
ode K
it
AcQ
Bla
te F
OR
CE
Se
nsin
g C
ath
ete
r
Qu
bic
Fo
rce
Mo
du
le
Qio
na
Irr
iga
tion
Pu
mp
Qu
bic
RF
Ge
ne
rato
r / C
on
tro
ller
Pu
lse
d F
ield
Ab
latio
n S
yste
m
No
t Y
et
Dis
clo
se
d
Not Y
et
Dis
clo
sed
No
t Y
et
Dis
clo
se
d
US
INT*
CommercialInvestigational Device or pending
approval/clearance in relevant markets Development
Our Journey to Become a Leading Electrophysiology Therapy Management Company
*Includes Acutus Direct Europe business and distribution markets through Biotronik
// 12 April 2021STRICTLY PRIVATE & CONFIDENTIAL 12
Grow installed base
We view our available market as
including every EP lab – this is not a
replacement market
X X
Increase procedures
per system per week
Convert multiple EP physicians
(and fellows) in each account
Spread usage across all arrhythmia
types -- from simple to complex,
including ventricular
Expand revenue
per procedure
Patient
Electrode
Patches
High-
Density
Mapping
Access Force
Sensing
Point
Ablation
Full Suite
of Septal
Crossing
Products
Diagnostic
Catheters
Fu
ture
To
day
Concentrated customer base in the U.S.*
~1,000EPs
~750Hospitals
& ~400kcardiac ablation
procedures each year
&
Model and Key Revenue DriversUp to $10K* revenue potential for disposables / procedure
*Data and analysis based on internal estimates
//
2021 Selected Catalysts and Key Milestones
12 April 2021 13
Initiation of AcQBlate Force Sensing Ablation Catheter US IDE for Right Atrial Flutter
US 510K clearance for the expanded family of AcQCross Integration Needle/Dilator
transseptal crossing devices
AcQMap 2.0 next generation mapping catheter CE Mark Approval
Data and abstract presentations at the annual Heart Rhythm Society Meeting
First-in-man and pilot trial work for Pulse Field Ablation (PFA)
Initiation of AcQBlate Force Sensing Ablation Catheter US IDE for Atrial Fibrillation
Completed Milestones Pending Developments
//
Several Factors Drive 2021 Sales Ramp
12 April 2021 14
Underlying market conditions and moderating impact of COVID restrictions
Manufacturing ramp for AcQBlate and transseptal access products
Timing of capital sales and conversions
Revenue uptake for anticipated new product approvals and launches
Improved US commercial execution
*We are not commenting on the quarter or outlook and will provide an update on financial performance on our May 12 th earnings call
Guidance as of Q4 Earnings Call*
1Q2021: $2.6-3.0 million FY2021: $22.0-30.0 million
//
Creating Long-term Shareholder Value
12 April 2021 15
• Internal R&D teams are
consistently delivering market-
relevant and differentiated new
products
• Augment organic efforts through
select licensing and partnership
opportunities
• Leadership changes bringing the
right capabilities to our team
• Training and developing our therapy
managers to support technology
and new product adoption
• Biotronik partnership extends our
access to global market
• Manufacturing footprint supports
long-term growth
• Gross margins should improve
meaningfully with scale
• Managing expenses to maximize
allocation to growth-oriented
investments
Technology
and Innovation
Leadership
Commercial
Execution
Operational
Excellence
Comprehensive Portfolio
and Robust Pipeline
Drive Adoption and
Shift the Paradigm
Well-Positioned for
Long-Term Scale
We will execute our strategy and drive shareholder value through:
//
Stay Connected with Acutus
12 April 2021 16
IssuerAcutus Medical, Inc.
Exchange / TickerNASDAQ: AFIB
Investor ContactCaroline Corner
415-202-5678
@AcutusMedical
linkedin.com/company/acutus-medical-inc-/
@AcutusMedical
Acutus Medical
acutus.com